stapling with its 90° articulation capability, providing surgeons with the maneuverability and precision necessary to perform effective stapling even in the most confined spaces. This innovation potentially reduces the need for multiple stapler...
first compounded semaglutide gummy. Designed to deliver the benefits of GLP-1 medications in a convenient, needle-free format, this innovative format reimagines how individuals approach GLP-1 programs in the United States. Eden believes a healthier...
statements due to certain factors, e.g., changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the...
said Dr. Stephen Weeks, VP of Structural Biology at Orthogon Therapeutics. “This achievement highlights our platform’s ability to target previously undruggable viral proteins.” This breakthrough coincides with Orthogon’s creation of a pioneering...
and better outcomes for patients worldwide. "This collaboration marks a significant step forward in our mission to transform lupus nephritis treatment," said Dr. Alon Yaar, CEO of LIVEKIDNEY.BIO. "By joining forces with Isotopia, we are confident...
pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics' CD19-directed ADC...
Petauri, a leading purpose-built pharmaceutical services platform, announced that Nicole Lodowski, Managing Director of Petauri Evidence, has been recognized as one of MM+M's esteemed 40 Under 40 honorees for 2025. Amanda Peterson, Vice President...
a cross-border functional team and fostering external collaborations to maintain an agile, cost-efficient development platform, driving its efforts to create groundbreaking therapies. For more information please visit https://www.pilatusbio.com/.
obesity therapies, including Semaglutide and Orforglipron, providing robust support for BLX-7006's potential as a transformative treatment for obesity & diabetic indications. The newly completed study builds upon a previous DIO study in which...
compensate for sphincter insufficiency in patients, both men and women, with SUI. It is based on a unique mechatronic platform using embedded smart, digital and robotic systems which, based on data collected from a patient, create a treatment...
research career at Rockefeller University. I was investigating a fundamental question: How do 100 billion connections form in our brain to empower humans to do everything we do? That led me to an interest in ophthalmology, especially retina...
immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, United Arab Emirates and...
as Fast Track designation by the FDA. The company has built a strong pipeline by leveraging its proprietary technology platforms: PACbody®, SPECpair® and ATACCbody® to develop novel biologics that address high unmet medical needs in cancer. For...
exceed expectations and mark a significant milestone in the continued development of ST-001. ST-001 Clinical Trial Information: SciTech's initial trial is targeting T-cell non-Hodgkin lymphoma (T-cell NHL) indications including all sub-types of...
Eisai having final decision-making authority. In South Korea, Eisai Korea Inc. will distribute the product and conduct information provision activities. Eisai Korea Inc. has been a pioneer in the field of dementia for many years, focusing on...
of innovative I&I biological products. We look forward to his contributions and insights as we strive to bring transformative therapies to patients in need." About Scinai Immunotherapeutics: Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a...
Jennifer Tamberino – who had been Regional Business Director, East, National Sales –was promoted to backfill Foy's former position as national sales director. "It is with incredible excitement that we announce Don's promotion to lead our sales,...
Ventures Company opens up completely new opportunities for us to tap into further markets, expand our technology platform and develop new products,” said Ulrike Sailer, CEO of Neoplas Med. “We are not only taking a big step forward, but also...
with latest pharma research and novel treatments on the horizon. In addition, a multidisciplinary approach to drug formulation and delivery will be presented. This conference features state of the art presentations and discussions on current...
in Houston, USA, from November 6 to 10. BH3120 is a novel anticancer drug based on Hanmi's proprietary dual antibody platform, "Pentambody." This technology enables a single antibody to simultaneously bind to two distinct targets, allowing for a...
